Baxter International | BAX - Current Liabilities


Baxter International reported $3.69B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
AngioDynamics USD 71.96M 3.68M Sep/2025
Artivion USD 92.7M 8.86M Mar/2026
AtriCure USD 73.19M 8.33M Mar/2026
Avanos Medical USD 131.2M 34M Mar/2026
Baxter International USD 3.69B 723M Mar/2026
Becton, Dickinson and Co. USD 8.51B 254M Mar/2026
Boston Scientific USD 4.57B 868M Mar/2026
Cooper Companies USD 1.8B 209M Mar/2026
Dexcom USD 2.22B 81.3M Mar/2026
Edwards Lifesciences USD 1.41B 404.7M Mar/2026
Fresenius EUR 8.38B 1.18B Dec/2025
Globus Medical USD 482.46M 16.04M Mar/2026
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
ICU Medical USD 517.9M 19.04M Mar/2026
Inogen USD 64.94M 2.12M Sep/2025
Insulet USD 687.5M 7.4M Mar/2026
Integra LifeSciences USD 346.85M 109.14M Mar/2026
Intuitive Surgical USD 2.51B 3.2M Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Laboratory Of America USD 2.64B 182.5M Mar/2026
Medtronic USD 9.5B 440M Dec/2025
Merit Medical Systems USD 216.87M 22.89M Mar/2026
Quest Diagnostics USD 2.18B 101M Mar/2026
Smith & Nephew USD 1.54B 236M Dec/2025
Stryker USD 6.32B 1.48B Mar/2026
Tandem Diabetes Care USD 247.96M 5.24M Mar/2026
Teleflex USD 728.05M 33.98M Mar/2026
Terumo JPY 540.73B 1.03B Mar/2026
Zimmer Biomet Holdings USD 2.86B 280.6M Mar/2026